Aytu BioPharma, Inc.
AYTU
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $23.7M
$2.21
▼ -3.28%
P/E
10.52
Mkt Cap
$23.7M
52-Wk Range
$1.65–$3.07
52-Week Range
$1.65 - $3.07
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 2.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Profitability at risk
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-1.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AYTU right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 29, 2026
Most recent quarter reported revenue of $13.9M. Reported EPS of $0.21.
Reported EPS · last 4Q
Q1 26
$0.21
Revenue trend · last 1Q
—
Q1 26
$13.9M
Margins · last 1Q
Profit
14.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AYTU stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.